OmniComm Systems Signs Letter of Intent to Acquire Certain Assets of Algorithm and its Subsidiary Algorics


Acquisition Will Expand OmniComm's Product Line With Data Analytics and Risk-Based Monitoring Solutions

FORT LAUDERDALE, Fla., Nov. 21, 2017 (GLOBE NEWSWIRE) -- OmniComm Systems, Inc. (OTCQX:OMCM), a leading global provider of clinical data management technology, and  Algorithm, Inc. and its subsidiaries Algorics Ltd. and Algorithm Informatics Pvt. Ltd. (collectively, "Algorics"), have signed a letter of intent ("LOI"), under which OmniComm will acquire certain assets and assume certain liabilities of Algorics, a provider of clinical analytics solutions and software. By combining forces, the companies expect increased operating efficiency, strengthened traction in the maturing risk-based approach solution area, new marketing opportunities and an expanded portfolio of electronic data capture (EDC) solutions for the global clinical trials industry. The transaction would also provide OmniComm with an office in India, a country of growing importance in the clinical trials market.

The proposed acquisition will cement the existing collaboration between the companies and provide OmniComm with access to advanced data analytics capabilities and specialized algorithms, including artificial intelligence/machine learning, developed by Algorics.

"We've been partnering with OmniComm for the last two and a half years. The companies are a very good fit culturally, with a high compatibility of technologies and shared vision for clinical trials innovation," said Nithiya Ananthakrishnan, CEO and founder of Algorics. "Algorics has developed algorithms and software to address the increasing demands from global regulatory bodies for reduced regulatory risk, improved quality and compliance with real-time insight. Joining OmniComm will accelerate our goal of becoming the best-in-class solution for risk-based monitoring and clinical data analytics. We look forward to bringing additional competitive advantages to OmniComm's customers by delivering end-to-end RBM solutions and specialized data analytics expertise."

With two decades of operating experience, OmniComm will provide the Algorics team with an established and expanding marketplace. The acquisition will enable OmniComm to diversify and increase its product line. Additional benefits include:

  • Enhanced real-time and cross-study reporting capabilities for OmniComm's TrialMaster® and TrialOne® product lines.
  • AI/Machine-learning capabilities for remote monitoring of research sites.
  • End-to-end risk management framework in compliance with the recent ICH GCP E6 Addendum.
  • Expanded regional customer support in the Asia-Pacific market.
  • An office in India, which has become increasingly important for research and development initiatives in the pharmaceutical market.

"This acquisition fills a strong need for our customer base in the area of data aggregation and analytics, cross-study reporting and risk-based monitoring support," said Stephen Johnson, president and CEO of OmniComm. "The Acuity platform from Algorics perfectly complements and integrates with our TrialMaster EDC platform to improve clinical trials data quality, enhance our current risk-based monitoring capabilities and enable our clients to make better, real-time decisions throughout their clinical research."

OmniComm and Algorics both use the Microsoft Technology Stack, so the integration with TrialMaster and TrialOne is seamless, Mr. Johnson added.

No finder's fees are payable as a result of the proposed acquisition. Completion of the proposed acquisition is subject to a number of conditions including, but not limited to completion of satisfactory due diligence during a ninety (90) day due diligence period, the negotiation and execution of a definitive asset purchase agreement and approval of the Board of Directors of OmniComm. There can be no assurance that the transaction will be completed as proposed. The proposed acquisition is expected to close by the first quarter of 2018.

About Algorics
Algorics brings together a team of highly experienced software and life science professionals, united behind a single goal: to provide innovative risk-based monitoring and clinical analytics solutions and software to the global life sciences industry with consistent and reliable quality. Please visit for more information.

About OmniComm Systems, Inc.
OmniComm Systems, Inc. is a leading strategic software solutions provider to the life sciences industry. OmniComm is dedicated to helping the world's pharmaceutical, biotechnology, contract research organizations (CROs), diagnostic and device firms, and academic medical centers maximize the value of their clinical research investments. Through the use of innovative and progressive technologies, these organizations drive efficiency in clinical development, better manage risks, ensure regulatory compliance and manage their clinical operations performance. OmniComm provides comprehensive solutions for clinical research with an extensive global experience from more than 5,000 clinical trials. Please visit for more information.

OmniComm, TrialMaster, TrialOne and Promasys are registered trademarks of OmniComm Systems, Inc. Other names may be trademarks of their respective owners.

Forward Looking Statements 
This document contains forward-looking statements that involve risks, uncertainties and assumptions. If any of these risks or uncertainties materializes or any of these assumptions proves incorrect, the results of OMCM and its consolidated subsidiaries could differ materially from those expressed or implied by such forward-looking statements.

All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including any projections of any financial items; any statements of the plans, strategies, and objectives of management for future operations, including the execution of integration and restructuring plans and the anticipated timing of closing relating to the planned acquisition; any statements concerning proposed new products, services, developments or industry rankings; any statements regarding future economic conditions or performance; any statements of belief and any statements of assumptions underlying any of the foregoing.

The risks, uncertainties and assumptions referred to above include the ability of OMCM to retain and motivate key employees; the timely development, production and acceptance of products and services and their feature sets; the difficulty of keeping expense growth at modest levels while increasing revenues; the challenges of integration and restructuring associated with the acquisition and the challenges of achieving anticipated synergies; the possibility that the planned acquisitions may not close and the other risks and uncertainties detailed in Part I, Item 1A. "Risk Factors," in the Company's Annual Report on Form 10-K for the year ended December 31, 2016 and in the Company's other filings made from time to time with the SEC (copies of which may be obtained through the Investor Relations portion of the Company's website under "SEC Filings").

The Company assumes no obligation to and does not intend to update these forward-looking statements.

Contact Info
Investor Relations
OmniComm Systems, Inc.

Nithiya Ananthakrishnan

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: OmniComm Systems Inc. via Globenewswire




Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

Nitinat Provides Update on the Carscallen Gold Property19.3.2018 21:30Pressmeddelande

TORONTO, March 19, 2018 (GLOBE NEWSWIRE) -- Further to its press release dated March 12, 2018 whereby Nitinat Minerals Corp. (the "Corporation") (TSX-V:NZZ) (Frankfurt:04U1) announced its option to acquire four (4) additional claims (collectively, the "Claims") abutting the western boundaries of the Corporation's current mining claims in Carscallen Township, Ontario (the "Carscallen Gold Property"), the Corporation is pleased to provide additional information pertaining to the Claims. The Corporation intends to implement an exploration program for the Claims to fully explore the potential of the Claims. The "preliminary technical appraisal" provided herein, along with the geophysics that the Corporation intends to undertake, will identify potential drill targets. The property encompassing the Claims is of particular interest in that surface exploration to date on the Claims has shown the existence of historic surface mining and sampling. The Corporation is currently assessing the most

New Elemica Trace Solution Delivers Shipment Risk Analysis for Digital Transformation19.3.2018 13:09Pressmeddelande

Real-Time Information Matched with GPS Locations Provides Accurate Delivery Information WAYNE, Pa., March 19, 2018 (GLOBE NEWSWIRE) -- Elemica, the leading Digital Supply Network for process manufacturing industries, introduces Elemica Trace, a solution that provides real-time shipment and risk visibility to customer service, transport planners, and supply chain managers, allowing them to monitor and proactively manage the movement of products to customers and inbound to manufacturing centers. "Shipment disruptions occur and teams can spend hours manually tracking down what is happening. What's worse, sometimes your customer complaint is the first indication you have of a late shipment," said Rich Katz, CTO of Elemica. "Trace eliminates the time and stress of tracking shipments and enables your teams to increase the positive interactions with your customers." Elemica Trace uses shipment data, carrier signals, a geo-location interface, and predictive algorithms to identify shipments in

Resverlogix Exceeds Full Enrollment for the Pivotal Phase 3 BETonMACE Clinical Trial19.3.2018 12:00Pressmeddelande

The BETonMACE trial has now surpassed 2,400 enrolled patients and topline data is expected around the end of 2018 CALGARY, Alberta, March 19, 2018 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it has successfully surpassed the planned enrollment target of over 2,400 patients in the ongoing Phase 3 BETonMACE trial. The trial's first patient was enrolled on November 11th, 2015. The goal of the trial is to confirm the effect of Resverlogix' lead drug, apabetalone, in Cardiovascular Disease (CVD) patients with type 2 Diabetes Mellitus (DM) and low high-density lipoproteins (HDL). The primary endpoint of the BETonMACE trial is designed to establish a relative risk reduction (RRR) of Major Adverse Cardiac Events (MACE), narrowly defined as a single composite endpoint of cardiovascular death, non-fatal myocardial infarction (MI) and stroke. Secondary pre-specified endpoints in the trial will also examine renal function and MACE in patien

SolarWinds Places Highest on the Ability to Execute Axis in 2018 Gartner Magic Quadrant for Network Performance Monitoring and Diagnostics19.3.2018 11:30Pressmeddelande

AUSTIN, Texas, March 19, 2018 (GLOBE NEWSWIRE) -- SolarWinds, a leading provider of powerful and affordable IT management software, placed highest on the ability to execute axis in the 2018 Gartner Magic Quadrant for Network Performance Monitoring and Diagnostics1. This Gartner report evaluated 22 suppliers of Network Performance Monitoring and Diagnostics products. The firm's evaluation criteria for ability to execute included the following: product or service, overall viability, sales execution and pricing, market responsiveness and record, marketing execution, customer experience, and operations. Of all the vendors evaluated in the report, SolarWinds placed highest on the ability to execute axis. "For three years in a row, Gartner has positioned us as highest on the ability to execute axis in the Magic Quadrant for Network Performance Monitoring and Diagnostics. In our view, this result confirms our commitment to helping our customers manage their network operations with a powerful

Record High Number of Toll Transactions Cleared in Ireland in 201719.3.2018 10:51Pressmeddelande

ISSY LES MOULINEAUX, France, March 19, 2018 (GLOBE NEWSWIRE) -- The number of transactions processed through emovis's toll interoperability cloud-based hub in Ireland has reached a record high with over 50 million transactions cleared in 2017. Thanks to its toll interoperability solution, emovis is contributing to the improved mobility of millions of Irish drivers, by allowing them to travel seamlessly with just one toll tag across the whole country. As of January 2018, over 650,000 toll transponders are in use. With this new success, emovis demonstrates its leadership in designing and operating innovative mobility solutions that offer the best levels of service for road users in Ireland and throughout the world. About emovis was awarded the contract for managing Ireland's toll interoperability hub by the National Roads Authority (now Transport Infrastructure Ireland) in June 2013 following a competitive tender. As part of this contract, emovis designed, developed and is curre

Karolinska Development's portfolio company Forendo Pharma granted a €3 million loan19.3.2018 09:30Pressmeddelande

STOCKHOLM, 19 March 2018. Karolinska Development's portfolio company Forendo Pharma announces a €3 million loan grant decision by Business Finland. The purpose of the loan is to support the development of a novel drug for endometriosis treatment. Currently available treatments for endometriosis have limitations in efficacy or cause harmful side effects, due to estrogen depletion. Research findings discovered in Finland have opened new opportunities for targeting endometriotic lesions by inhibiting HSD17B1 enzyme. Forendo Pharma's lead program, the HSD17B1 inhibitor FOR-6219, is about to enter the clinical development phase. The new funding from Business Finland will be used to strengthen Forendo's women's health portfolio with a DUAL HSD (hydroxysteroid dehydrogenase) Inhibitor program, targeting gynaecological conditions, including endometriosis. The DUAL HSD Inhibitor program was initiated in 2016 and Forendo is planning to select the product candidate for further development in 2019

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum